

REMARKS

The Examiner has requested restriction of the present invention in accordance with 37 CFR 1.499 to:

Group I, claim(s) 1, 3-5, 7-10 and 14, drawn to a combination comprising: (a) death receptor ligand, and (b) a histone deacetylase inhibitor of Formula (I).


Group II, claim(s) 2, 6 and 11-13, drawn to a method for the prevention or treatment of proliferative diseases, in a mammal, which comprises treating the mammal with pharmaceutically effective amounts of a combination of: (a) death receptor ligand, and (b) a histone deacetylase inhibitor of formula (I).

Without traverse Applicants elect Group II. Claims 1, 3-5, 7-10 and 14 are withdrawn as not being elected material. Applicants reserve their right to file divisional(s) to nonelected claim(s).

The Examiner has requested a species for examination purposes. Applicants elect the histone deacetylase inhibitor, *N*-hydroxy-3-[4-[[[2-(2-methyl-1*H*-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2*E*-2-propenamide and the death receptor ligand, TRAIL/Apo-2L.

Should the Examiner have any questions, please contact the undersigned attorney.

Respectfully submitted,



Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

Novartis Pharmaceuticals Corp.
Patents Pharma
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-2614

Date: July 17, 2008